IIS: HL7 Standard Code Set
Mapping product names to CVX and MVX
CDC Product Names reflect manufacturer trade names, but may not be identical to those registered trade names. The reason that these names vary from the manufacturers trade name is that they must reflect a unique product. Several vaccines have the same trade name for both the pediatric and the adult formulations of a vaccine.
CVX codes are codes that indicate the product used in a vaccination. MVX codes are codes that indicate the manufacturer of a vaccine. These codes are maintained by the Centers for Disease Control and Prevention, Immunization Information System Support Branch (IISSB) for use in HL7 data transmission.
The goal of the table is to support mapping of product names to CVX and MVX codes.
Questions regarding this table should be directed to the IIS Technical Assistance Team(or use mailing address).
Sort Table by Column: Simply click on the column heading to sort the table accordingly.
| CDC Product Name | Short Description | CVX Code | Manufacturer | MVX Code | MVX status | Product name status | Last Updated Date |
|---|---|---|---|---|---|---|---|
| ACAM2000 | vaccinia (smallpox) | 75 | Emergent BioSolutions | MIP | Active | Active | 6/10/2022 |
| ACAM2000 | vaccinia (smallpox) | 75 | Acambis, Inc | ACA | Inactive | Inactive | 5/28/2010 |
| ACEL-IMUNE | DTaP | 20 | Inactive | Inactive | 9/1/2010 | ||
| ACTHIB | Hib (PRP-T) | 48 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| ADACEL | Tdap | 115 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| Adenovirus types 4 and 7 | Adenovirus types 4 and 7 | 143 | TEVA Pharmaceuticals USA | TVA | Active | Active | 7/23/2019 |
| Adenovirus types 4 and 7 | Adenovirus types 4 and 7 | 143 | Barr Laboratories | BRR | Inactive | Inactive | 7/30/2019 |
| Afluria | Influenza, seasonal, injectable | 141 | Seqirus | SEQ | Active | Active | 9/26/2016 |
| AFLURIA | Influenza, seasonal, injectable | 141 | bioCSL | CSL | Inactive | Inactive | 9/26/2016 |
| Afluria quadrivalent preservative free | influenza, injectable, quadrivalent, preservative free | 150 | Seqirus | SEQ | Active | Active | 10/4/2016 |
| Afluria quadrivalent, preservative free, pediatric | Influenza, injectable,quadrivalent, preservative free, pediatric | 161 | Seqirus | SEQ | Active | Active | 8/26/2019 |
| Afluria, preservative free | Influenza, seasonal, injectable, preservative free | 140 | bioCSL | CSL | Inactive | Inactive | 12/15/2022 |
| Afluria, preservative free | Influenza, seasonal, injectable, preservative free | 140 | Seqirus | SEQ | Active | Inactive | 12/15/2022 |
| Afluria, quadrivalent | influenza, injectable, quadrivalent | 158 | Seqirus | SEQ | Active | Active | 10/4/2016 |
| AGRIFLU | Influenza, seasonal, injectable, preservative free | 140 | Novartis Pharmaceutical Corporation | NOV | Inactive | Inactive | 11/15/2017 |
| AS03 adjuvant | AS03 Adjuvant | 801 | GlaxoSmithKline | SKB | Active | Inactive | 9/11/2015 |
| AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD) | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | 210 | AstraZeneca | ASZ | Active | Active | 10/18/2022 |
| ATTENUVAX | measles | 05 | Merck and Co., Inc. | MSD | Active | Inactive | 4/28/2015 |
| Bexsero | meningococcal B, OMV | 163 | GlaxoSmithKline | SKB | Active | Active | 3/22/2016 |
| Bexsero | meningococcal B, OMV | 163 | Novartis Pharmaceutical Corporation | NOV | Inactive | Active | 2/2/2015 |
| BIAVAX II | rubella/mumps | 38 | Inactive | Inactive | 9/1/2010 | ||
| BIOTHRAX | anthrax | 24 | Emergent BioSolutions | MIP | Active | Active | 8/9/2013 |
| BOOSTRIX | Tdap | 115 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| CERTIVA | DTaP | 20 | Inactive | Inactive | 9/1/2010 | ||
| CERVARIX | HPV, bivalent | 118 | GlaxoSmithKline | SKB | Active | Inactive | 11/22/2016 |
| COMIRNATY | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | 208 | Pfizer, Inc | PFR | Active | Active | 5/18/2022 |
| COMIRNATY | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | 217 | Pfizer, Inc | PFR | Active | Active | 5/18/2022 |
| COMVAX | Hib-Hep B | 51 | Merck and Co., Inc. | MSD | Active | Inactive | 3/11/2016 |
| CONVIDECIA (CanSino Biologics) COVID-19 Vaccine | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | 506 | CanSino Biologics, Inc | CAN | Active | Active | 11/1/2022 |
| Coronavac (Sinovac) COVID-19 Vaccine | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | 511 | Sinovac | SNV | Active | Active | 7/13/2021 |
| COVAXIN (Bharat) COVID-19 Vaccine | COVID-19 IV Non-US Vaccine (COVAXIN) | 502 | Bharat Biotech International Limited | BBI | Active | Active | 11/1/2022 |
| Covifenz | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | 512 | Medicago, Inc | MDO | Active | Active | 4/11/2022 |
| DAPTACEL | DTaP, 5 pertussis antigens | 106 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| DECAVAC | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | 113 | Sanofi Pasteur | PMC | Active | Inactive | 10/27/2017 |
| DENGVAXIA | dengue fever tetravalent | 56 | Sanofi Pasteur | PMC | Active | Active | 9/4/2019 |
| DRYVAX | vaccinia (smallpox) | 75 | Inactive | Inactive | 9/1/2010 | ||
| DT(GENERIC) | DT (pediatric) | 28 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| ENGERIX B-PEDS | Hep B, adolescent or pediatric | 08 | GlaxoSmithKline | SKB | Active | Active | 8/9/2013 |
| ENGERIX-B-ADULT | Hep B, adult | 43 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| ERVEBO (Ebola Zaire Vaccine, Live) | Ebola Zaire vaccine, live, recombinant, 1mL dose | 204 | Merck and Co., Inc. | MSD | Active | Active | 1/12/2023 |
| Fluad | influenza, trivalent, adjuvanted | 168 | Seqirus | SEQ | Active | Active | 8/9/2016 |
| Fluad | influenza, trivalent, adjuvanted | 168 | Novartis Pharmaceutical Corporation | NOV | Inactive | Active | 8/9/2016 |
| FLUAD Quadrivalent | Influenza vaccine, quadrivalent, adjuvanted | 205 | Seqirus | SEQ | Active | Active | 7/20/2020 |
| FLUARIX | Influenza, seasonal, injectable, preservative free | 140 | GlaxoSmithKline | SKB | Active | Inactive | 12/15/2022 |
| Fluarix, quadrivalent, preservative free | influenza, injectable, quadrivalent, preservative free | 150 | GlaxoSmithKline | SKB | Active | Active | 8/9/2013 |
| Flublok | influenza, recombinant, injectable, preservative free | 155 | Protein Sciences | PSC | Active | Active | 5/28/2013 |
| Flublok quadrivalent | influenza, recombinant, quadrivalent,injectable, preservative free | 185 | Sanofi Pasteur | PMC | Active | Active | 5/2/2019 |
| Flublok quadrivalent | influenza, recombinant, quadrivalent,injectable, preservative free | 185 | Protein Sciences | PSC | Active | Inactive | 5/2/2019 |
| Flucelvax | Influenza, injectable, MDCK, preservative free | 153 | Novartis Pharmaceutical Corporation | NOV | Inactive | Inactive | 6/24/2016 |
| flucelvax, quadrivalent, preservative free | Influenza, injectable, MDCK, preservative free, quadrivalent | 171 | Seqirus | SEQ | Active | Active | 6/16/2016 |
| Flucelvax, quadrivalent, with preservative | Influenza, injectable, MDCK, quadrivalent, preservative | 186 | Seqirus | SEQ | Active | Active | 6/27/2017 |
| FLULAVAL | Influenza, seasonal, injectable | 141 | ID Biomedical | IDB | Active | Active | 9/10/2013 |
| Flulaval quadrivalent | influenza, injectable, quadrivalent | 158 | ID Biomedical | IDB | Active | Active | 9/10/2013 |
| Flulaval, preservative free | Influenza, seasonal, injectable, preservative free | 140 | ID Biomedical | IDB | Active | Inactive | 12/15/2022 |
| Flulaval, quadrivalent, preservative free | influenza, injectable, quadrivalent, preservative free | 150 | ID Biomedical | IDB | Active | Active | 10/21/2014 |
| FLUMIST | influenza, live, intranasal | 111 | MedImmune, Inc. (AstraZeneca) | MED | Active | Inactive | 10/23/2015 |
| Flumist quadrivalent | influenza, live, intranasal, quadrivalent | 149 | MedImmune, Inc. (AstraZeneca) | MED | Active | Active | 8/7/2012 |
| FLUVIRIN | Influenza, seasonal, injectable | 141 | Novartis Pharmaceutical Corporation | NOV | Inactive | Active | 9/27/2010 |
| Fluvirin | Influenza, seasonal, injectable | 141 | Seqirus | SEQ | Active | Active | 6/12/2017 |
| Fluvirin preservative free | Influenza, seasonal, injectable, preservative free | 140 | Seqirus | SEQ | Active | Inactive | 12/15/2022 |
| FLUVIRIN-PRESERVATIVE FREE | Influenza, seasonal, injectable, preservative free | 140 | Novartis Pharmaceutical Corporation | NOV | Inactive | Inactive | 12/15/2022 |
| FLUZONE | Influenza, seasonal, injectable | 141 | Sanofi Pasteur | PMC | Active | Active | 9/27/2010 |
| FLUZONE High-Dose Quadrivalent | influenza, high-dose, quadrivalent | 197 | Sanofi Pasteur | PMC | Active | Active | 1/29/2020 |
| FLUZONE High-Dose Quadrivalent Southern Hemisphere | influenza, Southern Hemisphere, high-dose, quadrivalent | 231 | Sanofi Pasteur | PMC | Active | Active | 3/14/2023 |
| Fluzone Quad Intradermal | influenza, intradermal, quadrivalent, preservative free | 166 | Sanofi Pasteur | PMC | Active | Inactive | 12/15/2022 |
| FLUZONE Quadrivalent Southern Hemisphere | influenza, Southern Hemisphere, preservative free | 201 | Sanofi Pasteur | PMC | Active | Active | 3/12/2020 |
| FLUZONE Quadrivalent Southern Hemisphere | influenza, Southern Hemisphere, quadrivalent, with preservative | 202 | Sanofi Pasteur | PMC | Active | Active | 3/12/2020 |
| FLUZONE Quadrivalent Southern Hemisphere, Pediatric | influenza, Southern Hemisphere, pediatric, preservative free | 200 | Sanofi Pasteur | PMC | Active | Active | 4/21/2020 |
| Fluzone Quadrivalent, pediatric | Influenza, injectable,quadrivalent, preservative free, pediatric | 161 | Sanofi Pasteur | PMC | Active | Active | 7/23/2014 |
| Fluzone, intradermal | influenza, seasonal, intradermal, preservative free | 144 | Sanofi Pasteur | PMC | Active | Inactive | 12/15/2022 |
| Fluzone, Quadrivalent | influenza, injectable, quadrivalent | 158 | Sanofi Pasteur | PMC | Active | Active | 8/8/2013 |
| Fluzone, quadrivalent, preservative free | influenza, injectable, quadrivalent, preservative free | 150 | Sanofi Pasteur | PMC | Active | Active | 10/21/2014 |
| FLUZONE-HIGH DOSE | Influenza, high dose seasonal | 135 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| FLUZONE-PRESERVATIVE FREE | Influenza, seasonal, injectable, preservative free | 140 | Sanofi Pasteur | PMC | Active | Inactive | 12/15/2022 |
| GARDASIL | HPV, quadrivalent | 62 | Merck and Co., Inc. | MSD | Active | Inactive | 5/28/2010 |
| Gardasil 9 | HPV9 | 165 | Merck and Co., Inc. | MSD | Active | Active | 12/11/2014 |
| HAVRIX-ADULT | Hep A, adult | 52 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| HAVRIX-PEDS | Hep A, ped/adol, 2 dose | 83 | GlaxoSmithKline | SKB | Active | Active | 8/9/2013 |
| HEPLISAV-B | HepB-CpG | 189 | Dynavax, Inc. | DVX | Active | Active | 10/27/2017 |
| HIBERIX | Hib (PRP-T) | 48 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| HIBTITER | Hib (HbOC) | 47 | Inactive | Inactive | 8/18/2010 | ||
| Imovax | rabies, intramuscular injection | 18 | Sanofi Pasteur | PMC | Active | Inactive | 12/12/2016 |
| IMOVAX | Rabies - IM Diploid cell culture | 175 | Sanofi Pasteur | PMC | Active | Active | 10/19/2016 |
| IMOVAX ID | rabies, intradermal injection | 40 | Sanofi Pasteur | PMC | Active | Inactive | 11/22/2016 |
| INFANRIX | DTaP | 20 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| Influenza A (H5N1) -2013 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | 160 | ID Biomedical | IDB | Active | Active | 1/16/2014 |
| Influenza A monovalent (H5N1), ADJUVANTED-2013 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | 160 | GlaxoSmithKline | SKB | Active | Inactive | 8/27/2015 |
| IPOL | IPV | 10 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| Ixiaro | Japanese Encephalitis IM | 134 | Valneva | VAL | Active | Active | 7/19/2016 |
| IXIARO | Japanese Encephalitis IM | 134 | Intercell Biomedical | INT | Inactive | Inactive | 7/19/2016 |
| IXIARO | Japanese Encephalitis IM | 134 | Vetter Pharma Fertigung GmbH & Co. KG | VET | Inactive | Active | 12/4/2017 |
| Janssen (J&J) COVID-19 Vaccine | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | 212 | Janssen | JSN | Active | Active | 7/12/2021 |
| JE-VAX | Japanese encephalitis SC | 39 | The Research Foundation for Microbial Diseases of Osaka University (BIKEN) | JPN | Inactive | Inactive | 4/29/2015 |
| JYNNEOS | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | 206 | Bavarian Nordic A/S | BN | Active | Active | 5/20/2022 |
| KINRIX | DTaP-IPV | 130 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| MENACTRA | meningococcal MCV4P | 114 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| MENHIBRIX | Meningococcal C/Y-HIB PRP | 148 | GlaxoSmithKline | SKB | Active | Inactive | 11/15/2017 |
| MENOMUNE | meningococcal MPSV4 | 32 | Sanofi Pasteur | PMC | Active | Inactive | 10/27/2017 |
| MenQuadfi | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | 203 | Sanofi Pasteur | PMC | Active | Active | 5/27/2020 |
| MENVEO | Meningococcal MCV4O | 136 | Novartis Pharmaceutical Corporation | NOV | Inactive | Active | 3/22/2016 |
| Menveo | Meningococcal MCV4O | 136 | GlaxoSmithKline | SKB | Active | Active | 3/22/2016 |
| MERUVAX II | rubella | 06 | Merck and Co., Inc. | MSD | Active | Inactive | 4/28/2015 |
| M-M-R II | MMR | 03 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| Moderna COVID-19 Bivalent, Original + BA.1 (Non-US Tradename Spikevax Bivalent) | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | 519 | Moderna US, Inc. | MOD | Active | Active | 11/17/2022 |
| Moderna COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename Spikevax Bivalent) | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | 229 | Moderna US, Inc. | MOD | Active | Active | 11/16/2022 |
| Moderna COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename Spikevax Bivalent) | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL | 230 | Moderna US, Inc. | MOD | Active | Active | 11/16/2022 |
| Moderna COVID-19 Vaccine (non-US Spikevax) | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | 221 | Moderna US, Inc. | MOD | Active | Active | 11/30/2022 |
| Moderna COVID-19 Vaccine (non-US Spikevax) | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | 228 | Moderna US, Inc. | MOD | Active | Active | 11/30/2022 |
| Moderna COVID-19 Vaccine (non-US Spikevax) | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | 207 | Moderna US, Inc. | MOD | Active | Active | 11/30/2022 |
| Moderna COVID-19 Vaccine (non-US Spikevax) | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | 227 | Moderna US, Inc. | MOD | Active | Active | 11/30/2022 |
| MUMPSVAX | mumps | 07 | Inactive | Inactive | 9/1/2010 | ||
| MYCOBAX | BCG | 19 | Inactive | Inactive | 12/11/2015 | ||
| Novavax COVID-19 Vaccine (Non-US Tradenames NUVAXOVID, COVOVAX) | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | 211 | Novavax, Inc. | NVX | Active | Active | 11/16/2022 |
| Novel influenza-H1N1-09 | Novel influenza-H1N1-09 | 127 | Novartis Pharmaceutical Corporation | NOV | Inactive | Inactive | 8/27/2015 |
| Novel influenza-H1N1-09 | Novel influenza-H1N1-09 | 127 | Sanofi Pasteur | PMC | Active | Inactive | 8/27/2015 |
| Novel influenza-H1N1-09 | Novel influenza-H1N1-09 | 127 | bioCSL | CSL | Inactive | Inactive | 8/27/2015 |
| Novel Influenza-H1N1-09, nasal | Novel Influenza-H1N1-09, nasal | 125 | MedImmune, Inc. (AstraZeneca) | MED | Active | Inactive | 8/27/2015 |
| Novel influenza-H1N1-09, preservative-free | Novel influenza-H1N1-09, preservative-free | 126 | bioCSL | CSL | Inactive | Inactive | 8/27/2015 |
| Novel influenza-H1N1-09, preservative-free | Novel influenza-H1N1-09, preservative-free | 126 | Sanofi Pasteur | PMC | Active | Inactive | 8/27/2015 |
| Novel influenza-H1N1-09, preservative-free | Novel influenza-H1N1-09, preservative-free | 126 | Novartis Pharmaceutical Corporation | NOV | Inactive | Inactive | 8/27/2015 |
| OMNIHIB | Hib (PRP-T) | 48 | Inactive | Inactive | 9/1/2010 | ||
| ORIMUNE | OPV | 02 | Inactive | Inactive | 9/1/2010 | ||
| PEDIARIX | DTaP-Hep B-IPV | 110 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| PEDVAXHIB | Hib (PRP-OMP) | 49 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| PENTACEL | DTaP-Hib-IPV | 120 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| Pfizer COVID-19 Bivalent, Original + BA.1 (Non-US Tradename COMIRNATY Bivalent) | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | 520 | Pfizer, Inc | PFR | Active | Active | 11/17/2022 |
| Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) | COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose | 300 | Pfizer, Inc | PFR | Active | Active | 11/16/2022 |
| Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | 302 | Pfizer, Inc | PFR | Active | Active | 11/16/2022 |
| Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose | 301 | Pfizer, Inc | PFR | Active | Active | 11/16/2022 |
| Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | 218 | Pfizer, Inc | PFR | Active | Active | 9/10/2021 |
| Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | 217 | Pfizer, Inc | PFR | Active | Active | 9/10/2021 |
| Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | 208 | Pfizer, Inc | PFR | Active | Active | 9/10/2021 |
| Pfizer-BioNTech COVID-19 Vaccine (EUA labeled) COMIRNATY (BLA labeled) | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | 219 | Pfizer, Inc | PFR | Active | Active | 9/10/2021 |
| PNEUMOVAX 23 | pneumococcal polysaccharide PPV23 | 33 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| PREHEVBRIO Hepatitis B Vaccine (Recombinant) | HepB recombinant, 3-antigen, Al(OH)3 | 220 | VBI Vaccines, Inc | VBI | Active | Active | 1/25/2022 |
| PREVNAR 13 | Pneumococcal conjugate PCV 13 | 133 | Pfizer, Inc | PFR | Active | Active | 5/28/2010 |
| PREVNAR 13 | Pneumococcal conjugate PCV 13 | 133 | Wyeth | WAL | Active | Inactive | 5/28/2010 |
| PREVNAR 20 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | 216 | Pfizer, Inc | PFR | Active | Active | 8/18/2021 |
| PREVNAR 7 | pneumococcal conjugate PCV 7 | 100 | Wyeth | WAL | Active | Inactive | 9/24/2015 |
| PREVNAR 7 | pneumococcal conjugate PCV 7 | 100 | Wyeth | WAL | Active | Inactive | 9/24/2015 |
| Priorix | MMR | 03 | GlaxoSmithKline | SKB | Active | Active | 6/15/2022 |
| PROHIBIT | Hib (PRP-D) | 46 | Inactive | Inactive | 9/1/2010 | ||
| PROQUAD | MMRV | 94 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| Quadracel | DTaP-IPV | 130 | Sanofi Pasteur | PMC | Active | Active | 3/26/2015 |
| RABAVERT | Rabies - IM fibroblast culture | 176 | GlaxoSmithKline | SKB | Active | Active | 10/19/2016 |
| RABAVERT | Rabies - IM fibroblast culture | 176 | Novartis Pharmaceutical Corporation | NOV | Inactive | Inactive | 10/19/2016 |
| RabAvert | rabies, intramuscular injection | 18 | Chiron Corporation | CHI | Inactive | Inactive | 3/22/2016 |
| RECOMBIVAX-ADULT | Hep B, adult | 43 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| RECOMBIVAX-DIALYSIS | Hep B, dialysis | 44 | Merck and Co., Inc. | MSD | Active | Active | 8/9/2013 |
| RECOMBIVAX-PEDS | Hep B, adolescent or pediatric | 08 | Merck and Co., Inc. | MSD | Active | Active | 8/9/2013 |
| ROTARIX | rotavirus, monovalent | 119 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| ROTATEQ | rotavirus, pentavalent | 116 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| Sanofi COVID-19 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | 225 | Sanofi Pasteur | PMC | Active | Active | 10/18/2022 |
| Sanofi COVID-19 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL | 226 | Sanofi Pasteur | PMC | Active | Active | 10/18/2022 |
| SHINGRIX | zoster recombinant | 187 | GlaxoSmithKline | SKB | Active | Active | 10/27/2017 |
| Sinopharm (BIBP) COVID-19 Vaccine | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | 510 | Sinopharm-Biotech | SPH | Active | Active | 7/13/2021 |
| SPIKEVAX | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | 207 | Moderna US, Inc. | MOD | Active | Active | 5/18/2022 |
| Stamaril | Yellow fever vaccine - alt | 183 | Sanofi Pasteur | PMC | Active | Active | 3/2/2017 |
| Td, adsorbed | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | 09 | Grifols | GRF | Active | Inactive | 5/21/2019 |
| Td, adsorbed | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | 09 | Massachusetts Biologic Laboratories | MBL | Active | Inactive | 5/21/2019 |
| TDVAX | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | 09 | Massachusetts Biologic Laboratories | MBL | Active | Active | 5/21/2019 |
| Tenivac | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | 113 | Sanofi Pasteur | PMC | Active | Active | 8/9/2013 |
| TETANUS TOXOID (GENERIC) | tetanus toxoid, adsorbed | 35 | Sanofi Pasteur | PMC | Active | Inactive | 5/28/2010 |
| TETRAMUNE | DTP-Hib | 22 | Inactive | Inactive | 9/1/2010 | ||
| TICE BCG | BCG | 19 | Merck and Co., Inc. | MSD | Active | Active | 7/26/2021 |
| TICOVAC | Tick-borne encephalitis, inactivated, PF, 0.5mL | 224 | Pfizer, Inc | PFR | Active | Active | 11/4/2021 |
| TICOVAC | Tick-borne encephalitis, inactivated, PF, 0.25mL | 223 | Pfizer, Inc | PFR | Active | Active | 11/4/2021 |
| TRIHIBIT | DTaP-Hib | 50 | Sanofi Pasteur | PMC | Active | Inactive | 3/21/2017 |
| TRIPEDIA | DTaP | 20 | Sanofi Pasteur | PMC | Active | Inactive | 11/15/2017 |
| Trumenba | meningococcal B, recombinant | 162 | Pfizer, Inc | PFR | Active | Active | 11/3/2014 |
| TWINRIX | Hep A-Hep B | 104 | GlaxoSmithKline | SKB | Active | Active | 5/28/2010 |
| TYPHIM VI | typhoid, ViCPs | 101 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| TYPHOID-AKD | typhoid, parenteral, AKD (U.S. military) | 53 | Inactive | Inactive | 8/9/2013 | ||
| VAQTA-ADULT | Hep A, adult | 52 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| VAQTA-PEDS | Hep A, ped/adol, 2 dose | 83 | Merck and Co., Inc. | MSD | Active | Active | 8/9/2013 |
| VARIVAX | varicella | 21 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
| VAXCHORA | cholera, live attenuated | 174 | Emergent Travel Health, Inc (Formerly PaxVax) | PAX | Active | Active | 6/17/2016 |
| VAXELIS | DTaP,IPV,Hib,HepB | 146 | MSP Vaccine Company - (partnership Merck and Sanofi Pasteur) | MSP | Active | Active | 7/21/2021 |
| VAXNEUVANCE | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | 215 | Merck and Co., Inc. | MSD | Active | Active | 8/18/2021 |
| Vivotif | typhoid, oral | 25 | Emergent Travel Health, Inc (Formerly PaxVax) | PAX | Active | Active | 7/23/2021 |
| VIVOTIF BERNA | typhoid, oral | 25 | Crucell | CRU | Inactive | Inactive | 5/2/2016 |
| YF-VAX | yellow fever | 37 | Sanofi Pasteur | PMC | Active | Active | 5/28/2010 |
| ZOSTAVAX | zoster live | 121 | Merck and Co., Inc. | MSD | Active | Active | 5/28/2010 |
For further information on HL7 immunization data exchange and the CVX code set, contact the IIS Technical Assistance Team at:
Address:
CDC, National Centers for Immunization and Respiratory DiseasesEmail:
Immunization Information System Support Branch - Informatics
1600 Clifton Road
Mailstop: E-62
Atlanta, GA 30333
iisinfo@cdc.gov (note change)
Page last reviewed: March 21, 2023
Content source: National Center for Immunization and Respiratory Diseases